

Behavioural Neurologist

Baycrest Centre for Geriatric Care is seeking a board certified neurologist with expertise in Behavioural Neurology to participate in an academic and clinical program in neurobehaviour within the Division of Neurology, University of Toronto.

Salary commensurate with qualifications and experience.

Send CV and letter of intent to:

Dr. Morris Freedman
Director, Behavioural Neurology Program
Baycrest Centre for Geriatric Care
3560 Bathurst St.
Toronto, ON
M6A 2E1

Closing date for receipt of applications: January 2, 1998

In accordance with its employment equity policy, the University of Toronto encourages applications from qualified women and men, members of visible minorities, aboriginal peoples and persons with disabilities. In accordance with Canadian Immigration requirements this advertisement is directed to Canadian citizens and permanent residents.

Pediatric Neurologist

The Division of Pediatric Neurology, Department of Pediatrics, at Dalhousie University is seeking an academic Pediatric Neurologist. This position will be a clinical appointment, with periodic review. The successful candidate will join an established division of 3.5 physicians with a strong interest in clinical research.

Dalhousie University and the IWK-Grace Health Centre provide all tertiary Pediatric care for the 3 Canadian Maritime Provinces. The unique regional nature of the services offered provides a particularly stimulating clinical and research environment.

The predominant criteria for appointment are a major commitment to clinical teaching and care with significant scholarly contributions to the field of Pediatric Neurology. Candidates must hold FRCP(C) qualifications in Pediatrics or Neurology or equivalent.

In accordance with Canadian immigration requirements, this advertisement is directed to Canadian citizens and permanent residents. Dalhousie University is an Employment Equity/Affirmative Action Employer. The University encourages applications from qualified women, Aboriginal Peoples, racially visible persons and persons with disabilities.

Interested candidates should write to:

Dr. J.M. Dooley,
Chair Search Committee,
Neurology Division,
IWK-Grace Health Centre,
5850 University Avenue,
Halifax, Nova Scotia,
Canada B3J 3G9

GLAXO WELLCOME - CCNS FELLOWSHIP IN CLINICAL NEUROSCIENCES

This newly created fellowship has been established to support clinical neurosciences research in Canada in the fields of headache and epilepsy. The fellowship is valued at \$45,000 and will be awarded annually for a one year period. The first award will be tenable as from July 1st, 1997.

Candidates must be enrolled in or have completed a specialty program approved by the Royal College of Physicians and Surgeons of Canada.

Applications must be received by January 31, 1998.

Further details and instructions for applicants may be obtained from:

GW-CCNS Fellowship
Canadian Congress of Neurological Sciences
P.O. Box 4220, Station C
Calgary, Alberta T2T 5N1
Tel.: (403) 229-9544

GLAXO WELLCOME - CCSN BOURSE DE RECHERCHE CLINIQUE EN SCIENCES NEUROLOGIQUES

Une nouvelle bourse a été créé afin de soutenir la recherche clinique en sciences neurologiques au Canada, plus précisément pour le traitement de la céphalée et de l'épilepsie. D'une valeur de 45 000 \$, la bourse sera attribuée chaque année pour une période d'un an et prendra effet le 1er juillet 1997.

Les candidats doivent être inscrits à un programme de spécialité approuvé par le Collège royal des médecins et chirurgiens du Canada, ou l'avoir terminé.

Date limite de réception des demandes de bourse : le 31 janvier 1998.

Pour obtenir plus de précisions, écrire à l'adresse suivante :

Bourse de recherche GW-CCSN
Congrès canadien des sciences neurologiques
P.O. Box 4220, Station C
Calgary, Alberta T2T 5N1
Tél. : (403) 229-9544



ÉPILEPSIE

**Lorsque l'objectif
thérapeutique est
la maîtrise complète
des crises**

**Maîtrise complète des crises
chez un pourcentage
impressionnant de patients¹**

**Frisium est «un antiépileptique
remarquablement efficace
et [généralement] sûr d'emploi
lorsqu'il est ajouté au traitement»¹**

**Efficace contre tous les types
de crises, tant chez les adultes
que chez les enfants²**

**Prise unquotidienne,
de préférence au coucher[†]**

LARGE SPECTRE D'ACTION



P Frisium[®] (clobazam)

Une fois par jour[†]

[†] La dose quotidienne peut être fractionnée chez certains patients.

Frisium est indiqué comme traitement d'appoint chez les patients épileptiques dont l'état n'est pas maîtrisé de façon satisfaisante par le traitement antiépileptique utilisé. À l'instar des autres benzodiazépines, le clobazam doit être administré avec prudence aux patients, notamment aux personnes âgées. Les effets indésirables les plus fréquents (>1 %) comprennent la somnolence, les étourdissements, la fatigue, l'ataxie, le gain pondéral, la nervosité, les troubles du comportement, l'hostilité et la vision brouillée.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc.
2150, boul. St-Elzéar Ouest
Laval (Québec) H7L 4A8

CCPP ACIM

FRI 96012 F

Hoechst[■]

Hoechst Marion Roussel
La société pharmaceutique de Hoechst

For brief prescribing information see page A-49



MIGRANAL Nasal Spray

**Relief that
keeps going
when others
have quit**

For Long-lasting relief[†]

- Long half-life: 10 hours¹
- After initial relief, migraine did not recur[§] in 85% of responders (n=73)²

For Fast relief

- Onset of relief within 30 minutes^{1,2}
- Up to 70% of migraines relieved at 4 hours (n=105)^{2††}
- Nasal administration bypasses the G.I. tract

Generally well-tolerated¹

- Most common adverse events in clinical trials were transient and self-limiting, and may be attributable to the route of administration^{2,3§§}

[†]Up to 24 hours with a single 2 mg dose

^{††}From moderate/severe pain to mild/no pain

[§]Recurrence = return of pain or other migraine symptoms within 24 hours

^{§§}Rhinitis (25% incidence) reported as rhinitis, rhinorrhea, nasal/nose congestion, dryness, edema and excessive sneezing; nausea (9%), taste disturbance (7%) and vomiting (4%). See Prescribing Information for details.

Migranal is a 5-HT₁ agonist for acute relief from migraine headaches, with or without aura, and associated symptoms. Migranal may be taken at any stage of a migraine headache. For best results, treatment should be initiated at the first sign/symptom of a migraine attack.¹

MIGRANAL
(dihydroergotamine mesylate nasal spray)

Fast migraine relief that lasts

For brief prescribing information see page A-26

 **NOVARTIS**

Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9R 4P5
Mfd. by Sandoz

MIG-97-07-3564E
*Registered trademark

PAAB MEMBER (PMA-C)